Technical Analysis for TGTX - TG Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Historical TGTX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Outside Day | Range Expansion | 0.00% | |
| MACD Bearish Centerline Cross | Bearish | -0.31% | |
| 50 DMA Resistance | Bearish | -4.39% | |
| Narrow Range Bar | Range Contraction | -4.39% | |
| NR7 | Range Contraction | -4.39% | |
| NR7-2 | Range Contraction | -4.39% | |
| 50 DMA Resistance | Bearish | -3.21% | |
| MACD Bearish Signal Line Cross | Bearish | -3.21% | |
| Narrow Range Bar | Range Contraction | -3.21% | |
| NR7 | Range Contraction | -3.21% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Trending on StockTwits | about 4 hours ago |
| Fell Below Previous Day's Low | about 9 hours ago |
| Lower Bollinger Band Support | about 9 hours ago |
| Down 1% | about 9 hours ago |
| 60 Minute Opening Range Breakdown | about 10 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/10/2021
TG Therapeutics, Inc. Description
TG Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company is developing two advanced therapies targeting hematological malignancies. The TGTX-1101 (ublituximab) is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes, which is in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. The TGR-1202 is an orally available PI3K delta inhibitor believed to be important in the proliferation and survival of B-lymphocytes. TG Therapeutics, Inc. is headquartered in New York, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Development Treatment Of Cancer Pharmaceutical Products Monoclonal Antibody Monoclonal Antibodies Lymphoma Antibody Drug Conjugates Hematological Malignancies Camidanlumab Tesirine Cd20 Lymphocytes
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 56.74 |
| 52 Week Low | 9.94 |
| Average Volume | 1,330,958 |
| 200-Day Moving Average | 34.96 |
| 50-Day Moving Average | 46.79 |
| 20-Day Moving Average | 46.67 |
| 10-Day Moving Average | 46.32 |
| Average True Range | 2.48 |
| ADX | 13.66 |
| +DI | 16.60 |
| -DI | 26.48 |
| Chandelier Exit (Long, 3 ATRs ) | 43.80 |
| Chandelier Exit (Short, 3 ATRs ) | 49.75 |
| Upper Bollinger Band | 50.29 |
| Lower Bollinger Band | 43.05 |
| Percent B (%b) | 0.22 |
| BandWidth | 15.51 |
| MACD Line | -0.43 |
| MACD Signal Line | -0.13 |
| MACD Histogram | -0.2967 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 47.30 | ||||
| Resistance 3 (R3) | 47.12 | 46.05 | 46.86 | ||
| Resistance 2 (R2) | 46.05 | 45.37 | 46.14 | 46.71 | |
| Resistance 1 (R1) | 45.35 | 44.96 | 45.70 | 45.53 | 46.57 |
| Pivot Point | 44.28 | 44.28 | 44.46 | 44.37 | 44.28 |
| Support 1 (S1) | 43.58 | 43.60 | 43.93 | 43.77 | 42.73 |
| Support 2 (S2) | 42.51 | 43.19 | 42.60 | 42.59 | |
| Support 3 (S3) | 41.81 | 42.51 | 42.44 | ||
| Support 4 (S4) | 42.00 |
